Russell Cohen (University of Chicago Medicine, Chicago, IL, US) spoke with touchIMMUNOLOGY around the optimal use of available therapies in the treatment of IBD. ‘Positioning Tofacitinib and Other Available Therapies’ was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
Questions
- Could you tell us a little about tofacitinib and its available formulations? (0:15)
- What key messages would you like to give to physicians regarding the optimal use of tofacitinib in the treatment of IBD? (0:57)
- What other JAK inhibitors are available or in clinical development for IBD? (1:56)
- What is the current status of S1P1 inhibitors in IBD and in which patients should they be considered? (2:54)
- Could you tell us a little about aprelimast and the potential of anti-phosphodiesterase therapy in IBD? (4:20)
Disclosures: Speaker’s Bureau for Abbvie and Takeda; Consultant / Advisory/ Scientific Advisory Board for Abbvie Laboratories, BMS/ Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda and UCB Pharma; Clinical Trials /Grants (Principal Investigator; active) for Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
